The primary aim of phase-I oncology trials is to establish the safety profiles of new anti-cancer agents. Fit patients with cancer, without standard treatment option, can consider participation. Patients may struggle to decide whether to engage in this kind of research with unknown efficacy, benefit, and side effects, or to opt for symptom-oriented palliative care. In this thesis, both medical outcomes of phase-I clinical trials as well as research towards patients‘ perspectives are presented.